Active, not recruitingPhase 2/3
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
Key facts
- Who runs it
- Sun Pharmaceutical Industries, Inc.
- Where
- Bakersfield, Bexley, Birmingham, Boca Raton, Boise, Boston, Canoga Park, Centennial, Charleston, Charlotte, Charlottesville, Chicago, Clarkston, Clinton Township, Columbus, Dallas, Denver, East Greenwich, Encinitas, Fort Smith, Fountain Inn, Fridley, Frisco, Hackensack, Hollywood, Houston, Indianapolis, Irvine, Kenosha, Las Vegas, Los Angeles, Louisville, Miami, Minneapolis, New Albany, New Haven, New York, Northridge, Oakland, Owensboro, Palm Springs, Pflugerville, Philadelphia, Phoenix, Plainfield, Plymouth Meeting, Portland, Providence, Raleigh, Redwood City, Richmond, Rochester, Rogers, Sacramento, San Antonio, San Francisco, Scottsdale, Sweetwater, Tampa, Tulsa, Upper Saint Clair, Verona, West Jordan, and Winston-Salem, United StatesSee the 72 sitesAlso in 1 other country, 19 sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 2/3
- People taking part
- 1,000 people, planned
- Started
- 4 Apr 2019
- Expected to end
- Jun 2027
- Type of study
- Interventional
- Treatments tested
- CTP-543
- Record updated
- 22 October 2025
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial
Who cannot take part
- Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study medication
- Donation of blood at any point throughout the study and for 30 days after last dose of study medication
- Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis
Where in United States
Also in 1 other country, 19 sites
- Kern Research, IncBakersfield, United StatesNo longer taking part
- Bexley Dermatology ResearchBexley, United StatesNo longer taking part
- Total Skin and Beauty Dermatology CenterBirmingham, United StatesNo longer taking part
- Skin Care Research, LLCBoca Raton, United StatesNo longer taking part
- ASR, LLCBoise, United StatesNo longer taking part
- Brigham and Women's HospitalBoston, United StatesNo longer taking part
- Massachusetts General HospitalBoston, United StatesNo longer taking part
- Hope Clinical ResearchCanoga Park, United StatesNo longer taking part
- Colorado Center for Dermatology, PLLC d/b/a CODerm ResearchCentennial, United StatesNo longer taking part
- Clinical Research Center of the CarolinasCharleston, United StatesNo longer taking part
- Darst DermatologyCharlotte, United StatesNo longer taking part
- Dermatology Specialists of CharlotteCharlotte, United StatesNo longer taking part
- University of Virginia Health SystemCharlottesville, United StatesNo longer taking part
- DeNova ResearchChicago, United StatesNo longer taking part
- Clarkston Skin ResearchClarkston, United StatesNo longer taking part
- Clinical Research Institute of MichiganClinton Township, United StatesNo longer taking part
- Remington Davis, Inc.Columbus, United StatesNo longer taking part
- Dermatology Treatment and Research Center - DallasDallas, United StatesNo longer taking part
- Colorado Medical Research CenterDenver, United StatesNo longer taking part
- Velocity Clinical Research, ProvidenceEast Greenwich, United StatesNo longer taking part
- California Dermatology & Clinical Research InstituteEncinitas, United StatesNo longer taking part
- Johnson DermatologyFort Smith, United StatesNo longer taking part
- Palmetto Clinical Trial ServicesFountain Inn, United StatesNo longer taking part
- Minnesota Clinical Study CenterFridley, United StatesNo longer taking part
- North Texas Center for Clinical ResearchFrisco, United StatesNo longer taking part
- Skin Laser and Surgery Specialists of NJHackensack, United StatesNo longer taking part
- Skin Care Research, LlcHollywood, United StatesNo longer taking part
- Suzanne Bruce and Associates, PAHouston, United StatesNo longer taking part
- Dawes Fretzin Clinical Research Group, LLCIndianapolis, United StatesNo longer taking part
- University of California, IrvineIrvine, United StatesNo longer taking part
- Clinical Investigation Specialists, Inc.Kenosha, United StatesNo longer taking part
- Vivida DermatologyLas Vegas, United StatesNo longer taking part
- Dermatology Research AssociatesLos Angeles, United StatesNo longer taking part
- Ds ResearchLouisville, United StatesNo longer taking part
- Floridian Research Institute LlcMiami, United StatesNo longer taking part
- University of Miami HospitalMiami, United StatesNo longer taking part
- University of Minnesota Department of DermatologyMinneapolis, United StatesNo longer taking part
- DS ResearchNew Albany, United StatesNo longer taking part
- Yale University Church Street Research UnitNew Haven, United StatesNo longer taking part
- Icahn School of Medicine at Mount SinaiNew York, United StatesNo longer taking part
- Sadick Research GroupNew York, United StatesNo longer taking part
- Quest Dermatology ResearchNorthridge, United StatesNo longer taking part
- Kaiser Permanente Northern California - OaklandOakland, United StatesNo longer taking part
- Qualmedica ResearchOwensboro, United StatesNo longer taking part
- Palmtree Clinical Research, Inc.Palm Springs, United StatesNo longer taking part
- Austin Institute for Clinical Research, Inc.Pflugerville, United StatesNo longer taking part
- Hospital of the University of Pennsylvania Dept of DermatologyPhiladelphia, United StatesNo longer taking part
- Alliance Dermatology & MOHS CenterPhoenix, United StatesNo longer taking part
- The Indiana Clinical Trials Center, PCPlainfield, United StatesNo longer taking part
- Dermatology Associates of Plymouth MeetingPlymouth Meeting, United StatesNo longer taking part
- NW Dermatology InstitutePortland, United StatesNo longer taking part
- Oregon Medical Research CenterPortland, United StatesNo longer taking part
- Rhode Island HospitalProvidence, United StatesNo longer taking part
- North Carolina Dermatology Associates, PLLCRaleigh, United StatesNo longer taking part
- Stanford University School of Medicine - Medical Dermatology ClinicRedwood City, United StatesNo longer taking part
- West End Dermatology AssociatesRichmond, United StatesNo longer taking part
- UR Dermatology at College TownRochester, United StatesNo longer taking part
- Northwest Arkansas Clinical Trials Center, PLLCRogers, United StatesNo longer taking part
- Kaiser Permanente-South SacramentoSacramento, United StatesNo longer taking part
- Dermatology Clinical Research Center of San AntonioSan Antonio, United StatesNo longer taking part
- Progressive Clinical ResearchSan Antonio, United StatesNo longer taking part
- Texas Dermatology and Laser SpecialistsSan Antonio, United StatesNo longer taking part
- Kaiser Permanente Clinical Trials UnitSan Francisco, United StatesNo longer taking part
- Center for Dermatology and Plastic Surgery/CCT ResearchScottsdale, United StatesNo longer taking part
- LENUS Research & Medical Group, LLCSweetwater, United StatesNo longer taking part
- Clinical Research Trials of Florida, Inc.Tampa, United StatesNo longer taking part
- ForCare Clinical ResearchTampa, United StatesNo longer taking part
- Vital Prospects Clinical Research Institute, P.C.Tulsa, United StatesNo longer taking part
- Peak Research - PennsylvaniaUpper Saint Clair, United StatesNo longer taking part
- Schweiger Dermatology, P.C.Verona, United StatesNo longer taking part
- Jordan Valley DermatologyWest Jordan, United StatesNo longer taking part
- Wake Forest University Health Sciences Department of DermatologyWinston-Salem, United StatesNo longer taking part
About the trial
What the trial wants to find out
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.
The group in the trial
- CTP-543Treatment being tested
Patients who previously completed a qualifying CTP-543 clinical trial
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata
- Publications
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial.Journal of the American Academy of Dermatology, 2026
- Record updated
- 22 October 2025